We have located links that may give you full text access.
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Antitumor effect of FP3 on a patient-derived tumor tissue xenograft model of rectal carcinoma.
Hepato-gastroenterology 2013 November
BACKGROUND/AIMS: FP3 is an engineered protein which contains the extracellular domain 2 of VEGF receptor 1 (Flt-1) and extracellular domain 3 and 4 of VEGF receptor 2 (Flk-1, KDR) fused to the Fc portion of human immunoglobulin G1. Previous studies demonstrated its antiangiogenic and antitumor effects in vitro and in vivo.
METHODOLOGY: In this study, a PDTT xenograft model of rectal carcinoma was established for assessment of the antitumor activity of FP3. Xenografts were treated with FP3 or bevacizumab (Avastin). After tumor growth was confirmed, volume and microvessel density in tumors were evaluated. Levels of VEGF and PCNA in the tumor were examined by immunohistonchemical staining and western blotting.
RESULTS: FP3 showed significant antitumor activity in the PDTT xenograft model of rectal carcinoma. The microvessel density in tumor tissues treated with FP3 was lower than that of the control. Antitumor activity of FP3 was similar to that of bevacizumab in the PDTT xenograft model of rectal carcinoma.
CONCLUSIONS: This study indicated that FP3 could be used as an effective antiangiogenic and antitumor agent in treatment of colorectal carcinoma.
METHODOLOGY: In this study, a PDTT xenograft model of rectal carcinoma was established for assessment of the antitumor activity of FP3. Xenografts were treated with FP3 or bevacizumab (Avastin). After tumor growth was confirmed, volume and microvessel density in tumors were evaluated. Levels of VEGF and PCNA in the tumor were examined by immunohistonchemical staining and western blotting.
RESULTS: FP3 showed significant antitumor activity in the PDTT xenograft model of rectal carcinoma. The microvessel density in tumor tissues treated with FP3 was lower than that of the control. Antitumor activity of FP3 was similar to that of bevacizumab in the PDTT xenograft model of rectal carcinoma.
CONCLUSIONS: This study indicated that FP3 could be used as an effective antiangiogenic and antitumor agent in treatment of colorectal carcinoma.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app